Pfizer, Eli Lilly: FDA Accepts Regulatory Submission for Tanezumab

Pfizer Inc. and Eli Lilly & Co. on Monday said the U.S. Food and Drug Administration accepted their biologics license application for their non-opioid pain drug tanezumab.
The drug makers said the application covers 2.5-milligram doses of tanezumab administered subcutaneously for patients with chronic pain due to moderate-to-severe osteoarthritis who have experienced inadequate pain relief with other analgesics.
Pfizer and Eli Lilly said the FDA set a target action date for December, and that the agency plans to hold an advisory committee meeting to discuss the application.
Pfizer and Lilly in 2013 formed a worldwide collaboration to develop and commercialize tanezumab, part of an investigational class of non-opioid chronic pain medications known as nerve growth factor inhibitors.

https://www.marketscreener.com/ELI-LILLY-AND-COMPANY-13401/news/Pfizer-Eli-Lilly-FDA-Accepts-Regulatory-Submission-for-Tanezumab-30092823/